Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled.
Avadel Pharmaceuticals Soars as Alkermes Announces $2.1 Billion Acquisition DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (
NASDAQ: AVDL ) shareholders are celebrating today as Alkermes plc (
NASDAQ: ALKS ) announced a definitive agreement to acquire the company for a staggering $2.1 billion. The news sent Avadel's stock price soaring in premarket trading, reflecting a significant premium offered to its investors.
Avadel Jumps On $2.1 Billion Takeover Deal. But Buyer, Alkermes, Dives. The companies are both working in the sleep space, focusing on excessive daytime sleepiness.
Avadel Pharmaceuticals (NASDAQ:AVDL) Surges 6.3% in Pre-Market as Q2 Earnings Crush Estimates on Strong LUMRYZ Performance Avadel Pharmaceuticals (AVDL) beats Q2 2025 estimates with $68.1M revenue and $0.10 EPS, driven by strong LUMRYZ™ adoption. Stock surges 6.3% pre-market.
Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz ASL demands Avadel replace its board over failures in marketing Lumryz and urging a review of strategic options
Avadel Pharmaceuticals Under Fire? Investor Reportedly Demands Board Ouster, Sale Talks, $1B In Damages ASL Strategic Value Fund plans to vote its $15 million stake against all Avadel board nominees at the July meeting and is pushing for contingent-value rights tied to potential legal payouts, according to a WSJ report.
3 Stocks With Robust Growth Outlooks Insiders Are Buying Insiders are buying these three stocks. The underlying companies have robust growth outlooks and are on track to deliver in 2025.
There May Still Be Time to Get in on These 3 Trending Biotechs Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ Avadel Pharmaceuticals missed the fourth quarter sales estimate by 5.12%. Still, the sales of its narcolepsy drug, LUMRYZ rose by 150% YoY.
AVDL Stock Earnings: Avadel Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 AVDL stock results show that Avadel Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82.
AVDL Stock Earnings: Avadel Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 AVDL stock results show that Avadel Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
